uttroside B

Uttroside B is a natural saponin isolated from the leaves of *Solanum nigrum* Linn., demonstrating superior preclinical efficacy against hepatocellular carcinoma (HCC) compared to sorafenib, the current first-line therapy. It induces potent cytotoxicity specifically in liver cancer cells (IC50 ~0.5 µM in HepG2 cells, ~10-fold more potent than sorafenib) via caspase-mediated apoptosis, downregulation of MAPK and mTOR pathways, and inhibition of JNK pro-survival signaling, while being non-toxic to normal hepatocytes even at high doses (up to 5x IC50). In vivo, it significantly reduces tumor volume in human HCC xenograft models with minimal reversible side effects, contrasting sorafenib's toxicity; it has received U.S. FDA orphan drug designation for HCC and is IND-ready following preclinical toxicology studies.[1][2][3][5][7]

Other names

Utt-B